Treating Retinal Diseases in the Era of Anti-VEGF Therapies

“Timely administration of the most effective treatment for retinal diseases, therefore not only improves patients’ functional ability and their potential to remain productive in society, but also decreases the social and economic burdens on society at large.”
Treating Retinal Diseases in the Era of Anti-VEGF Therapies, 2016


screen-shot-2016-10-07-at-9-00-31-amMany Canadians have benefited from the advent of anti-VEGF Therapies that have dramatically changed the treatment paradigm for a number of common and serious retinal diseases.  This has led to significantly improved prognosis and outcomes, including visual improvements and health-related quality of life, for many Canadians.

Over the last several months, the International Federation on Ageing (IFA) has worked with a group of Ontario retina specialists representing seven teaching hospitals to develop a position paper entitled Treating Retinal Diseases in the Era of Anti-VEGF Therapies.

The purpose of the paper is to provide the province with an expert perspective on the Canadian Agency for Drugs and Technologies in Health (CADTH) report entitled Anti-Vascular Endothelial Growth Factor Drugs for the Treatment of Retinal Conditions – Recommendations Report.

The IFA welcomes all organizations across Ontario to review the paper, but also re-post it and distribute it to your constituents. If your organization would like to be more involved in this initiative by endorsing this document, and thereby lending your voice moving forward, please do not hesitate to contact Dr. Jane Barratt, Secretary General of the IFA, at

Read the Treating Retinal Diseases in the Era of Anti-VEGF Therapies here.

For further information on the importance of advocating for options in eye health and to stay updated, please visit the Eye See You website.